Clinical utility of diagnostic markers for malignant pleural mesothelioma

Monaldi Archives for Chest Disease - Pulmonary Series

Volumn 71, Issue 1, 2009, Pages 31-38

  Grigoriu, Bogdan Dragos ^a,b,g   Grigoriu, C ^b,c   Chanine, B ^d,f   Gey, T ^e   Scherpereel, A ^a,f  

^a INSTITUT PASTEUR DE LILLE   (France)

^b GRIGORE T POPA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^c Department of Pathology   (Romania)

^d Hospital of Douai   (France)

^e Teissier Clinic   (France)

^f LILLE UNIVERSITY HOSPITAL   (France)

^g Clinic of Pulmonary Disease   (Romania)

Author keywords

Diagnosi; Markers; Mesothelioma; Peripheral blood; Pleural diseases

Indexed keywords

ANTINEOPLASTIC AGENT; ASBESTOS; CA 125 ANTIGEN; CA 15-3 ANTIGEN; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CYTOKERATIN; HYALURONIC ACID; HYBRID PROTEIN; MEGAKARYOCYTE POTENTIATING FACTOR; MESOTHELIN; OSTEOPONTIN; PROTEIN SSP1; TUMOR MARKER; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER SCREENING; CANCER SURVIVAL; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE MARKER; ENVIRONMENTAL EXPOSURE; HUMAN; INCIDENCE; MALIGNANT MESOTHELIOMA; MONITORING; PLEURA MESOTHELIOMA; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; SENSITIVITY AND SPECIFICITY;

EID: 65749101166     PISSN: 11220643     EISSN: 2465101X     Source Type: Journal    
DOI: 10.4081/monaldi.2009.374     Document Type: Review

References (103)

1. Herndon JE, Green MR, Chahinian AP, et al. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest 1999; 113: 723-31.
2. Wagner JC, Sleggs CA, Marchand P. Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province. Br J Ind Med 1960; 17: 260-71.
3. Vogelzang N, Rusthoven J, Symanowski J, et al. Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma. J Clin Oncol 2003; 21: 2636-2644.
4. Sugarbaker DJ, Flores RM, Jaklitsch MT, et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg 1999; 117: 54-63.
5. Walker AM, Loughlin JE, Friedlander ER, Rothman KJ, Dreyer NA. Projections of asbestos-related disease 1980-2009; J Occup Med 1983; 25: 409-25.
6. Stahel RA, Weder W, Felip E. Malignant pleural mesothelioma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2008; 19 Suppl 2: ii43-4.
7. Greillier L, Cavailles A, Fraticelli A, et al. Accuracy of pleural biopsy using thoracoscopy for the diagnosis of histologic subtype in patients with malignant pleural mesothelioma. Cancer 2007; 110: 2248-52.
8. Jassem J, Ramlau R, Santoro A, et al. Phase III trial of pernetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma. J Clin Oncol 2008; 26: 1698-1704.
9. Ceresoli, G.L., A. Chiti, P.A. Zucali, et al. Assessment of turnour response in malignant pleural mesothelioma. Cancer Treat Rev 2007; 33: 533-41.
10. Francis RJ, Byme MJ, van der Schaaf AA, et al. Early prediction of response to chemotherapy and survival in malignant pleural mesothelioma using a novel semiautomated 3-dimensional volume-based analysis of serial 18F-FDG PET scans. J Nucl Med 2007; 48: 1449-58.
11. Flores RM. The role of PET in the surgical management of malignant pleural mesothelioma. Lung Cancer 2005; 49 Suppl 1: S27-32.
12. Armato SG 3rd, Oxnard GR, MacMahon H, et al. Measurement of mesothelioma on thoracic CT scans: a comparison of manual and computer-assisted techniques. Med Phys 2004; 31: 1105-15.
13. Shi HZ, Liang QL, Jiang J, Qin XJ, Yang HB. Diagnostic value of carcinoembryonic antigen in malignant pleural effusion: a meta-analysis. Respirology 2008; 13: 518-27.
14. Thylen A, Hjerpe A, Martensson G. Hyaluronan content in pleural fluid as a prognostic factor in patients with malignant pleural mesothelioma. Cancer 2001; 92: 1224-30.
15. Hedman M, Arnberg H, Wernlund J, Riska H, Brodin O. Tissue polypeptide antigen (TPA), hyaluronan and CA 125 as serum markers in malignant mesothelioma. Anticancer Res 2003; 23: 531-6.
16. Frebourg T, Lerebours G, Delpech B, et al. Serum hyaluronate in malignant pleural mesothelioma. Cancer 1987; 59: 2104-7.
17. Boersma A, Degand P, Biserte G. Hyaluronic acid analysis and the diagnosis of pleural mesothelioma. Bull Eur Physiopathol Respir 1980; 16: 41-5.
18. Chiu B, Churg A, Tengblad A, Pearce R, McCaughey WT. Analysis of hyaluronic acid in the diagnosis of malignant mesothelioma. Cancer 1984; 54: 2195-9.
19. Fuhrman C, Duche JC, Chouaid C, et al. Use of tumour markers for differential diagnosis of mesothelioma and secondary pleural malignancies. Clin Biochem 2000; 33: 405-10.
20. Soderblom T, Pettersson T, Nyberg P, et al. High pleural fluid hyaluronan concentrations in rheumatoid arthritis. Eur Respir J 1999; 13: 519-22.
21. Atagi S, Ogawara M, Kawahara M, et al. Utility of hyaluronic acid in pleural fluid for differential diagnosis of pleural effusions: likelihood ratios for malignant mesothelioma. Jpn J Clin Oncol 1997; 27: 293-7.
22. Martensson G, Thylen A, Lindquist U, Hjerpe A. The sensitivity of hyaluronan analysis of pleural fluid from patients with malignant mesotheliorna and a comparison of different methods. Cancer 1994; 73: 1406-10.
23. Welker L, Muller M, Holz O, et al. Cytological diagnosis of malignant mesothelioma - improvement by additional analysis of hyaluronic acid in pleural effusions. Virchows Arch 2007; 450: 455-61.
24. van den Heuvel MM, Korse CM, Bonfrer JM, Baas P, Non-invasive diagnosis of pleural malignancies: the role of tumour markers. Lung Cancer 2008; 59: 350-4.
25. Alatas F, Alatas O, Metintas M, et al. Diagnostic value of CEA, CA 15-3, CA 19-9, CYFRA 21-1, NSE and TSA assay in pleural effusions. Lung Cancer 2001; 31: 9-16.
26. Nisman B, Barak V, Heching N, et al. Cytokeratin markers in malignant pleural mesothelioma. Cancer Detect Prev 1998; 22: 416-21.
27. Marukawa M, Hiyama J, Shiota Y, et al. The usefulness of CYFRA 21-1 in diagnosing and monitoring malignant pleural mesothelioma. Acta Med Okayama 1998; 52: p. 119-23.
28. Bonfrer JM, Schouwink JH, Korse CM, Baas P. Cyfra 21-1 and TPA as markers in malignant mesothelioma. Anticancer Res 1997; 17: 2971-3.
29. Paganuzzi M, Onetto M, Marroni P, et al. Diagnostic value of CYFRA 21-1 tumour marker and CEA in pleural effusion due to mesothelioma. Chest 2001; 119: 1138-42.
30. Creaney J, van Bruggen I, Hof M, et al. Combined CA125 and mesothelin levels for the diagnosis of malignant mesothelioma. Chest 2007; 132: 1239-1246.
31. Schouwink H, Korse CM, Bonfrer JM, Hart AA, Baas P. Prognostic value of the serum turnour markers Cyfra 21-1 and tissue polypeptide antigen in malignant mesothelioma. Lung Cancer 1999; 25: 25-32.
32. Chang K, Pai LH, Batra JK, Pastan I, Willingham MC. Characterization of the antigen (CAK1) recognized by monoclonal antibody K1 present on ovarian cancers and normal mesothelium. Cancer Res 1992; 52: 181-6.
33. Chang K, Pastan I. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci U S A 1996; 93: 136-40.
34. Bera TK, Pastan I. Mesothelin is not required for normal mouse development or reproduction. Mol Cell Biol 2000; 20: 2902-6.
35. Yamashita Y, Yokoyama M, Kobayashi E, Takai S, Hino O. Mapping and determination of the cDNA sequence of the Erc gene preferentially expressed in renal cell carcinoma in the Tsc2 gene mutant (Eker) rat model. Biochem Biophys Res Commun 2000; 275: 134-40.
36. Gubbels JA, Belisle J, Onda M, et al. Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumours. Mol Cancer 2006; 5: 50.
37. Kojima T, Oh-eda M, Hattori K, et al. Molecular cloning and expression of megakaryocyte potentiating factor cDNA. J Biol Chem 1995; 270: 21984-90.
38. Scholler N, Fu N, Yang Y, et al. Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma. Proc Natl Acad Sci U S A 1999; 96: 11531-6.
39. Chang K, Pastan I. Molecular cloning and expression of a cDNA encoding a protein detected by the K1 antibody from an ovarian carcinoma (OVCAR-3) cell line. Int J Cancer 1994; 57: 90-7.
40. Muminova ZE, Strong TV, Shaw DR. Characterization of human mesothelin transcripts in ovarian and pancreatic cancer. BMC Cancer 2004; 4: 19.
41. Sapede C, Gauvrit A, Barbieux I, et al. Aberrant splicing and protease involvement in mesothelin release from epithelioid mesothelioma cells. Cancer Sci 2008; 99: 590-4.
42. Hellstrom I, Raycraft J, Kanan S, et al. Mesothelin variant 1 is released from tumour cells as a diagnostic marker. Cancer Epidemiol Biomarkers Prev 2006; 15: 1014-20.
43. Ho M, Onda M, Wang QC, et al. Mesothelin is shed from tumour cells. Cancer Epidemiol Biomarkers Prev 2006; 15: 1751.
44. Onda M, Willingham M, Nagata S, et al. New monoclonal antibodies to mesothelin useful for immunohistochemistry, fluorescence-activated cell sorting, Western blotting, and ELISA. Clin Cancer Res 2005; 11: 5840-6.
45. Hassan R, Remaley AT, Sampson ML, et al. Detection and quantitation of serum mesothelin, a tumour marker for patients with mesothelioma and ovarian cancer. Clin Cancer Res 2006; 12: 447-53.
46. Shiomi K, Miyamoto H, Segawa T, et al. Novel ELISA system for detection of N-ERC/mesothelin in the sera of mesothelioma patients. Cancer Sci 2006; 97: 928-32.
47. Weber DG, Taeger D, Pesch B, et al. Soluble mesothelin-related peptides (SMRP) - high stability of a potential tumour marker for mesothelioma. Cancer Biomark 2007; 3: 287-92.
48. Di Serio F, Fontana A, Loizzi M, et al. Mesothelin family proteins and diagnosis of mesothelioma: analytical evaluation of an automated immunoassay and preliminary clinical results. Clin Chem Lab Med 2007; 45: 634-8.
49. Beyer HL, Geschwindt RD, Glover CL, et al. MESO-MARK: a potential test for malignant pleural mesothelioma. Clin Chem 2007; 53: 666-72.
50. Galateau-Salle F, Copin MC, Delajartre AY, et al. Which criteria for the anatomopathologic diagnosis of malignant pleural mesothelioma? Rev Mal Respir 2006; 23: 11S37-44.
51. Ordonez NG. The diagnostic utility of immunohistochemistry in distinguishing between epithelioid mesotheliomas and squamous carcinomas of the lung: a comparative study. Mod Pathol 2006; 19: 417-28.
52. Yaziji H, Battifora H, Barry TS, et al. Evaluation of 12 antibodies for distinguishing epithelioid mesothelioma from adenocarcinoma: identification of a three-antibody immunohistochemical panel with maximal sensitivity and specificity. Mod Pathol 2006; 19: 514-23.
53. Ordonez NG. The diagnostic utility of immunohistochemistry in distinguishing between mesothelioma and renal cell carcinoma: a comparative study. Hum Pathol 2004; 35: 697-710.
54. Ordonez NG. Value of mesothelin immunostaining in the diagnosis of mesothelioma. Mod Pathol 2003; 16: 192-7.
55. Ordonez NG. What are the current best immunohistochemical markers for the diagnosis of epithelioid mesothelioma? A review and update. Hum Pathol 2007; 38: 1-16.
56. Argani P, Iacobuzio-Donahue C, Ryu B, et al. Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin Cancer Res 2001; 7: 3862-8.
57. Ordonez NG. Application of mesothelin immunostaining in tumour diagnosis. Am J Surg Pathol 2003; 27: 1418-28.
58. Jhala N, Jhala D, Vickers SM, et al. Biomarkers in Diagnosis of pancreatic carcinoma in fine-needle aspirates. Am J Clin Pathol 2006; 126: 572-9.
59. Hassan R, Laszik ZG, Lerner M, et al. Mesothelin is overexpressed in pancreaticobiliary adenocarcinomas but not in normal pancreas and chronic pancreatitis. Am J Clin Pathol 2005; 124: 838-45.
60. Cao D, Maitra A, Saavedra JA, et al. Expression of novel markers of pancreatic ductal adenocarcinoma in pancreatic nonductal neoplasms: additional evidence of different genetic pathways. Mod Pathol 2005; 18: 752-61.
61. Kachali C, Eltoum I, Horton D, Chhieng DC. Use of mesothelin as a marker for mesothelial cells in cytologic specimens. Semin Diagn Pathol 2006; 23: 20-4.
62. Le Page C, Ouellet V, Madore J, et al. Gene expression profiling of primary cultures of ovarian epithelial cells identifies novel molecular classifiers of ovarian cancer. Br J Cancer 2006; 94: 436-45.
63. Drapkin R, Crum CP, Hecht JL. Expression of candidate tumour markers in ovarian carcinoma and benign ovary: evidence for a link between epithelial phenotype and neoplasia. Hum Pathol 2004; 35: 1014-21.
64. Hassan R, Kreitman RJ, Pastan I, Willingham MC. Localization of mesothelin in epithelial ovarian cancer. Appl Immunohistochem Mol Morphol 2005; 13: 243-7.
65. Huang CY, Cheng WF, Lee CN, et al. Serum mesothelin in epithelial ovarian carcinoma: a new screening marker and prognostic factor. Anticancer Res 2006; 26: 4721-8.
66. Yen MJ, Hsu CY, Mao TL, et al. Diffuse mesothelin expression correlates with prolonged patient survival in ovarian serous carcinoma. Clin Cancer Res 2006; 12: 827-31.
67. Robinson BW, Creaney J, Lake R, et al. Mesothelin-family proteins and diagnosis of mesothelioma. Lancet 2003; 362: 1612-6.
68. Creaney J, Christansen H, Lake R, et al. Soluble Mesothelin Related Protein in Mesothelioma. J Thoracic Oncol 2006; 1: 172-174.
69. Scherpereel A, Grigoriu B, Conti M, et al. Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma. Am J Respir Crit Care Med 2006; 173: 1155-60.
70. Grigoriu BD, Scherpereel A, Devos P, et al. Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment. Clin Cancer Res 2007; 13: 2928-35.
71. Amati M, Tomasetti M, Scartozzi M, et al. Profiling tumour-associated markers for early detection of malignant mesothelioma: an epidemiologic study. Cancer Epidemiol Biomarkers Prev 2008; 17: 163-70.
72. Cristaudo A, Foddis R, Vivaldi A, et al. Clinical significance of serum mesothelin in patients with mesothelioma and lung cancer. Clin Cancer Res 2007; 13: 5076-81.
73. Creaney J, Yeoman D, Demelker Y, et al. Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma. J Thorac Oncol 2008; 3: 851-7.
74. Creaney J, Yeoman D, Naumoff LK, et al. Soluble mesothelin in effusions: a useful tool for the diagnosis of malignant mesothelioma. Thorax 2007; 62: 569-76.
75. Pass HI, Wali A, Tang N, et al. Soluble Mesothelin-Related Peptide Level Elevation in Mesothelioma Serum and Pleural Effusions. Ann Thor Surg 2008; 85: 265-272.
76. Pass HI, Wolaniuk D, Wali A, et al. Soluble mesothelin related peptides: a potential biomarker for malignant pleural mesothelioma (abstract). J Clin Oncol (2005 ASCO Annual Meeting Abstracts) 2005; 23 (9532).
77. Grigoriu BD, Chahine B, Conti M, et al. Utility of serum soluble mesothelin as a follow-up marker in patients with malignant pleural mesothelioma (abstract). In European Respiratory Society Annnual Congress 2007; Stockholm.
78. Simonini S, Foddis R, Fitiberti R, et al. Evaluation of a series of serum mesothelin in patients with pleural malignant mesothelioma. G Ital Med Lav Ergon 2007; 29: 339-42.
79. Foddis R, Vivaldi A, Filiberti R, et al. Serum mesothelin dosages in follow-up of previously exposed workers. G Ital Med Lav Ergon 2007; 29: 342-5.
80. Roe OD, Creaney J, Lundgren S, et al. Mesothelin-related predictive and prognostic factors in malignant mesotheliorna: A nested case-control study. Lung Cancer 2008; 61: 235-243.
81. Park EK, Sandrini A, Yates DH, et al. Soluble mesothelin-related protein in an asbestos-exposed population: the dust diseases board cohort study. Am J Respir Crit Care Med 2008; 178: 832-7.
82. Cullen MR. Serum osteopontin levels - is it time to screen asbestos-exposed workers for pleural mesothelioma? N Engl J Med 2005; 353: 1617-8.
83. Onda M, Nagata S, Ho M, et al. Megakaryocyte potentiation factor cleaved from mesothelin precursor is a useful tumour marker in the serum of patients with mesothelioma. Clin Cancer Res 2006; 12: 4225-31.
84. Iwahori K, Osaki T, Serada S, et al. Megakaryocyte potentiating factor as a tumour marker of malignant pleural mesothelioma: Evaluation in comparison with mesothelin. Lung Cancer 2008; 2: 2.
85. Hassan R, BeraT, Pastan I. Mesothelin: a new target for immunotherapy. Clin Cancer Res 2004; 10: 3937-42.
86. Yokokawa J, Palena C, Arlen P, et al. Identification of novel human CTL epitopes and their agonist epitopes of mesothelin. Clin Cancer Res 2005; 11: 6342-51.
87. Hassan R, Wu C, Brechbiel MW, et al. 111Indium-labeled monoclonal antibody K1: biodistribution study in nude mice bearing a human carcinoma xenograft expressing mesothelin. Int J Cancer 1999; 80: 559-63.
88. Hassan R, Viner JL, Wang QC, et al. Anti-tumour activity of K1-LysPE38QQR, an immunotoxin targeting mesothelin, a cell-surface antigen overexpressed in ovarian cancer and malignant mesothelioma. J Immunother 2000; 23: 473-9.
89. Hassan R, Lerner MR, Benbrook D, et al. Antitumour activity of SS(dsFv)PE38 and SS1(dsFv)PE38, recombinant antimesothelin immunotoxins against human gynecologic cancers grown in organotypic culture in vitro. Clin Cancer Res 2002; 8: 3520-6.
90. Li Q, Verschraegen CF, Mendoza J, Hassan R. Cytotoxic activity of the recombinant anti-mesothelin immunotoxin, SSI(dsFv)PE38, towards tumour cell lines established from ascites of patients with peritoneal mesotheliomas. Anticancer Res 2004; 24: 1327-35.
91. Fan D, Yano S, Shinohara H. Targeted therapy against human lung cancer. Mol Cancer Ther 2002; 1: 595-600.
92. Hassan R, Williams-Gould J, Steinberg SM, et al. Tumour-directed radiation and the immunotoxin SS1P in the treatment of mesothelin-expressing tumour xenografts. Clin Cancer Res 2006; 12: 4983-8.
93. Zhang Y, Xiang L, Hassan R, et al. Synergistic antitumour activity of taxol and immunotoxin SS1P in tumour-bearing mice. Clin Cancer Res 2006; 12: 4695-701.
94. Kreitman R, Squires D, O'Hagan D, et al. SS1(dsFv)-PE38 anti-mesothelin immunotoxin in advanced malignancies: phase I study of continuous infusion. Proc Am Soc Clin Oncol 2002; 21: (abstr 1896).
95. Hassan R, Bullock S, Kindler H, Pastan I. Updated results of the phase I study of SS1(dsFv)PE38 for targeted therapy of mesothelin expressing cancers. Eur J Cancer 2004; 2: 280a.
96. Hassan R, Ho M. Mesothelin targeted cancer immunotherapy. Eur J Cancer 2008; 44: 46-53.
97. Wai PY, Kuo PC. The role of Osteopontin in tumour metastasis. J Surg Res 2004; 121: 228-41.
98. Ashkar S, Weber GF, Panoutsakopoulou V, et al. Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity. Science 2000; 287: 860-4.
99. Koguchi Y, Kawakami K, Uezu K, et al. High plasma osteopontin level and its relationship with interleukin-12-mediated type 1 T helper cell response in tuberculosis. Am J Respir Crit Care Med 2003; 167: 1355-9.
100. Vordermark D, Said HM, Katzer A, et al. Plasma osteopontin levels in patients with head and neck cancer and cervix cancer are critically dependent on the choice of ELISA system. BMC Cancer 2006; 6: 207.
101. Beck A, Ivanova A, Ivanov S, et al. Evaluation of plasma osteopontin as early detection and prognostic marker in malignant pleural mesothelioma. J Clin Oncol (Meeting Abstract) 2008; 26: 11074.
102. O'Regan AW, Serlin D, Berman JS. Asbestos exposure and serum osteopontin. N Engl J Med 2006; 354.
103. Cappia S, Righi L, Mirabelli D, et al. Prognostic role of osteopontin expression in malignant pleural mesothelioma. Am J Clin Pathol 2008; 130: 58-64.